 |
SINGAPORE, Sept. 12, 2018 /PRNewswire/ — Mundipharma has acquired the exclusive licensing rights for a number of P’tit Bobo children’s products to complement its existing BETADINETM consumer healthcare range in a deal covering the Middle East, Turkey and Africa region.
Available to children aged 6 months to 10 years, it includes Nasal Spray Isotonic for daily hygiene of nasal mucosa, Nasal Spray Hypertonic for nose decongestion in cases of runny and blocked nose, and Ear Spray to clean and safely prevent ear wax build-up. [1]
Young children are prone to bouts of flu and colds, with some falling sick as many as 8 to 10 times a year before they reach 2 years old. [3]
With the onset of the hotter summer months in the region, young children can suffer from flu-like symptoms as a result of spending time in air-conditioned buildings or from being around large numbers of people while travelling.
A good nasal hygiene routine may help to prevent nasal dryness, colds and other infections that can cause discomfort for a child. The use of isotonic and hypertonic saline solutions to relieve nasal congestion provide valuable support for children. [2],[3],[4],[5],[6]
These all-natural over-the-counter products offer parents and caretakers an easy option for managing these conditions in children, while reducing reliance on stronger, prescription medications, including antihistamines, antibiotics and corticosteroids in addressing the symptoms of acute Upper Respiratory Tract Infections. [2],[3],[4],[5],[6]
Mundipharma CEO, Raman Singh, said: “The introduction of this range to our consumer portfolio in the Middle East, Turkey and Africa will benefit children across the region.”
“The new products are proven to be effective in helping to alleviate some of the troublesome ear nose and throat symptoms that may affect toddlers and infants, and the fact that they are all-natural should encourage parents and caregivers to adopt a more proactive and regular approach to managing them.” [3],[4],[5],[6]
|
TM: BETADINE is a Trademark of Mundipharma. |
|
References: |
|
1. YSLAB Company website |
|
2. Culig J., et al. Efficiency of hypertonic and isotonic sea water solutions in chronic rhinosinusitis. Medicinski Glaskik, Vol.7, No.2 Aug. 2010. |
|
3. Colds in children Paediatric Child Health. 2005 Oct; 10(8): 493–495. |
|
4. Chirico G, Quartarone G, Mallefet P. Nasal congestion in infants and children: a literature review on efficacy and safety of non-pharmacological treatments. Minerva Pediatr. 2014 Dec;66(6):549-57. |
|
5. Saline Nasal Irrigation for Upper Respiratory Conditions. Am Fam Physician. Author manuscript; available in PMC 2009 Nov 17. Published in final edited form as: Am Fam Physician. 2009 Nov 15; 80(10): 1117–1119. |
|
6. Saline nasal irrigation: Its role as an adjunct treatment. Blake Papsin, Alison McTavish. Can Fam Physician. 2003 Feb; 49: 168–173. |
About Mundipharma
Mundipharma is a network of independent associated companies, which are privately owned entities, covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information, please visit: www.mundipharma.ae
Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO
